Y-mAbs Therapeutics (YMAB) Competitors $8.28 -0.29 (-3.38%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends YMAB vs. GLPG, XNCR, EVO, ARQT, KNSA, NRIX, IMCR, RCUS, OCUL, and MESOShould you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), Kiniksa Pharmaceuticals (KNSA), Nurix Therapeutics (NRIX), Immunocore (IMCR), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Y-mAbs Therapeutics vs. Galapagos Xencor Evotec Arcutis Biotherapeutics Kiniksa Pharmaceuticals Nurix Therapeutics Immunocore Arcus Biosciences Ocular Therapeutix Mesoblast Galapagos (NASDAQ:GLPG) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends. Do analysts rate GLPG or YMAB? Galapagos presently has a consensus price target of $30.75, indicating a potential upside of 14.91%. Y-mAbs Therapeutics has a consensus price target of $20.89, indicating a potential upside of 152.28%. Given Y-mAbs Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71Y-mAbs Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of GLPG or YMAB? 32.5% of Galapagos shares are held by institutional investors. Comparatively, 70.8% of Y-mAbs Therapeutics shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 22.5% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in GLPG or YMAB? Galapagos received 333 more outperform votes than Y-mAbs Therapeutics when rated by MarketBeat users. Likewise, 64.10% of users gave Galapagos an outperform vote while only 63.03% of users gave Y-mAbs Therapeutics an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.10% Underperform Votes26135.90% Y-mAbs TherapeuticsOutperform Votes13363.03% Underperform Votes7836.97% Which has more risk & volatility, GLPG or YMAB? Galapagos has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Which has higher earnings & valuation, GLPG or YMAB? Galapagos has higher revenue and earnings than Y-mAbs Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$260.09M6.78$229.12MN/AN/AY-mAbs Therapeutics$84.55M4.39-$21.43M-$0.54-15.33 Is GLPG or YMAB more profitable? Galapagos has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. Galapagos' return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Y-mAbs Therapeutics -28.22%-24.61%-18.49% Does the media refer more to GLPG or YMAB? In the previous week, Y-mAbs Therapeutics had 2 more articles in the media than Galapagos. MarketBeat recorded 4 mentions for Y-mAbs Therapeutics and 2 mentions for Galapagos. Galapagos' average media sentiment score of 0.68 beat Y-mAbs Therapeutics' score of 0.54 indicating that Galapagos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Y-mAbs Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGalapagos beats Y-mAbs Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMAB vs. The Competition Export to ExcelMetricY-mAbs TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$383.84M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-15.3310.5991.3417.19Price / Sales4.39195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book3.575.104.794.78Net Income-$21.43M$151.51M$120.07M$225.60M7 Day Performance-12.20%-2.15%-1.90%-1.23%1 Month Performance-18.02%-3.14%11.45%3.37%1 Year Performance31.64%11.50%30.63%16.58% Y-mAbs Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMABY-mAbs Therapeutics2.249 of 5 stars$8.28-3.4%$20.89+152.3%+35.7%$383.84M$84.55M-15.33150High Trading VolumeGLPGGalapagos0.6178 of 5 stars$27.03+0.8%$30.75+13.8%-31.4%$1.78B$260.09M0.001,123XNCRXencor4.3204 of 5 stars$25.29+5.2%$36.56+44.5%+18.4%$1.77B$168.34M-7.51280EVOEvotec2.387 of 5 stars$4.69+4.5%$5.93+26.5%-60.5%$1.66B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.8599 of 5 stars$13.38+5.4%$15.50+15.8%+478.8%$1.57B$138.71M-7.58150Options VolumePositive NewsKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.85+3.2%$36.60+75.5%+15.4%$1.51B$384.10M-144.29220Positive NewsNRIXNurix Therapeutics2.5066 of 5 stars$21.13+4.2%$30.35+43.6%+101.7%$1.50B$56.42M-6.97300News CoverageIMCRImmunocore2.4974 of 5 stars$29.88+3.4%$65.64+119.7%-51.4%$1.49B$296.31M-30.43497Short Interest ↓RCUSArcus Biosciences2.6476 of 5 stars$16.23+0.9%$34.00+109.5%-9.3%$1.49B$117M-5.11500News CoverageOCULOcular Therapeutix3.6461 of 5 stars$9.04+4.0%$16.71+84.9%+116.8%$1.42B$58.44M0.00267Positive NewsMESOMesoblast1.043 of 5 stars$12.23+4.0%$11.50-6.0%+590.1%$1.40B$5.90M0.0080Analyst ForecastOptions VolumeNews CoveragePositive News Related Companies and Tools Related Companies GLPG Competitors XNCR Competitors EVO Competitors ARQT Competitors KNSA Competitors NRIX Competitors IMCR Competitors RCUS Competitors OCUL Competitors MESO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:YMAB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts